Curis ca-4948 nhl ash presentation 2020
WebNov 29, 2024 · CA-4948 is a small molecule inhibitor of IRAK4 kinase that modulates the TLR and IL-1R signaling cascades. CA-4948 is being developed as a novel agent for the treatment of hematologic cancers with dysregulated IRAK4 signaling and is currently in a Ph1 trial for R/R NHL (clinicaltrials.gov NCT03328078). WebDec 7, 2024 · LEXINGTON, Mass., Dec. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Curis ca-4948 nhl ash presentation 2020
Did you know?
WebMay 13, 2024 · Curis, whose market cap now sits at nearly $1.5bn, has a lot riding on CA-4948. Its next most advanced asset is the anti-Vista monoclonal antibody CI-8993, on which phase 1 data is due in the second half of the year. Two further clinical-stage assets are on ice after earlier disappointments. WebMar 1, 2024 · Figure 2: Pipeline (Source: corporate presentation) CA-4948 goes after IRAK4 (first in class inhibitor) and CI-8993 is a monoclonal antibody first in class antagonist of VISTA (the third of 3 ...
WebMar 16, 2024 · In December 2024, Curis announced positive preliminary data from its ongoing Phase 1 study of CA-4948 monotherapy in patients with R/R AML and high-risk MDS, including marrow blast reductions observed in all evaluable patients and 2 of 6 evaluable patients experiencing a marrow complete response. WebDec 7, 2024 · Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory...
WebMay 12, 2024 · Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2024 Virtual Congress /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),... WebThis presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform ... NHL CA-4948* IRAK4 IL -1R/TLR altered AML, MDS Immune Checkpoint Inhibitors CA-170* PDL1/VISTA ... Booher et al. ASH 2016 (poster #4184) 4) Data from Curis ...
WebNov 4, 2024 · As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA ...
WebCuris CA-4948 NHL ASH Presentation 2024 - Curis, Inc About Company Overview Management Board of Directors History Collaborations Partner Collaborations Scientific & Research Collaborations Patients Patients Overview About Clinical Studies Current Studies Compassionate Use Policy Pipeline Pipeline Overview Emavusertib (CA-4948) CI-8993 … china waterproof synthetic leatherWebDec 7, 2024 · Curis slumps ( CRIS -25.0%) as investors seem to be disappointed on updated data from its ongoing Phase 1 study evaluating of CA-4948, an IRAK4 kinase inhibitor, for the treatment of relapsed... china waterproof tact switchWebNov 13, 2024 · A phase 1 trial in patients with NHL is being conducted to determine safety, pharmacokinetics, and preliminary efficacy of CA-4948 as monotherapy. Patients and Methods. At the 18-Jul-2024 data cut-off date, 22 patients have been treated with single-agent CA-4948. china waterproof phone holderWebNov 4, 2024 · Details of the presentations are as follows: Oral Presentation: Title: Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or... china waterproof military bagWebCA-4948 in patients expressing IRAK4-L •Capitalize on unique clinical experience with VISTA by in-licensing the leading monoclonal antibody program (CI-8993) and initiating a Ph1 study in solid tumors 2024 2024 2024 Initial Clinical Data Report preliminary efficacy data for CA-4948 Ph1 study in NHL Evaluate new published research in gran centurions clarkWebThis presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform ... (NHL) CA-4948* IRAK4 IRAK4L-expressing Leukemia (AML/MDS) Fimepinostat HDAC/PI3K MYC-altered ... In Nov 2024, the NCI selected CA-4948, Curis’s first-in ... china waterproof tact switch supplierWebCA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Guillermo Garcia-Manero, MD 1 , Uwe Platzbecker, MD², Stefanie Gropper, MD 3 , Chetasi Talati, MD 4 , Katharina S. Götze, MD 5 , James Dugan, MD 6 , Eric S. Winer, MD 7 , Christopher Lieberman 8 , gran charm